They started with a natural hormone called amylin and made specific changes to its structure to make it more effective and last longer in the body
The response peaked in the 10 to 10 molar range and did not show meaningful toxicity at the concentrations tested, which is relevant for product formulation: effective at trace amounts, without apparent harm at the tested range
From available case reports, compounding pharmacy data, and practitioner experience, the following have been observed: BPC-157 Reported Side Effects Nausea and gastrointestinal discomfort (especially with oral administration) Dizziness or light-headedness Flushing or warmth at injection sites Headache Fatigue or somnolence in some users TB-500 Reported Side Effects Injection site reactions (redness, mild pain, swelling) Transient fatigue or lethargy following administration Headache Possible flu-like symptoms in a minority of users Critical Risk Note: Because neither peptide has undergone full clinical trial evaluation in humans, the complete adverse event profile is unknown
The relationship between biological pathway activation and cancer development is far more complex than simple cause and effect
PubMed Vukojevic J, Siroglavic M, Kasun M, et al
It has a genuine FDA-approval history rather than being a novel "research chemical," but no FDA-approved finished product remains on the market, so it is supplied only through compounding pharmacies and prescribed off-label in adults for growth-hormone-axis support, general wellness, or anti-aging purposes rather than its original pediatric indication